A Phase II, Randomized, Two Stage, Double-Blind, Placebo-Controlled Two-Dose, Safety and Immunogenicity Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers.
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2012
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors BiondVax Pharmaceuticals
- 30 Jul 2012 Actual initiation date (July 2010) added as reported by ClinicalTrials.gov.
- 16 Jun 2011 Status changed from recruiting to completed as reported in a BiondVax media release.
- 16 Jun 2011 Results will be presented at the BIO International Convention.